By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Science Briefing
  • Medicine
  • Biology
  • Engineering
  • Environment
  • More
    • Dentistry
    • Chemistry
    • Physics
    • Agriculture
    • Business
    • Computer Science
    • Energy
    • Materials Science
    • Mathematics
    • Politics
    • Social Sciences
Notification
  • Home
  • My Feed
  • SubscribeNow
  • My Interests
  • My Saves
  • History
  • SurveysNew
Personalize
Science BriefingScience Briefing
Font ResizerAa
  • Home
  • My Feed
  • SubscribeNow
  • My Interests
  • My Saves
  • History
  • SurveysNew
Search
  • Quick Access
    • Home
    • Contact Us
    • Blog Index
    • History
    • My Saves
    • My Interests
    • My Feed
  • Categories
    • Business
    • Politics
    • Medicine
    • Biology

Top Stories

Explore the latest updated news!

Today’s Public Health Science Briefing | April 6th 2026, 9:00:31 am

Today’s Political Science Science Briefing | April 6th 2026, 9:00:31 am

Today’s Neurology Science Briefing | April 6th 2026, 9:00:31 am

Stay Connected

Find us on socials
248.1KFollowersLike
61.1KFollowersFollow
165KSubscribersSubscribe
Made by ThemeRuby using the Foxiz theme. Powered by WordPress

Home - Biology - Today’s Immunology Science Briefing | April 5th 2026, 9:00:31 am

Biology

Today’s Immunology Science Briefing | April 5th 2026, 9:00:31 am

Last updated: April 5, 2026 7:34 am
By
Science Briefing
ByScience Briefing
Science Communicator
Instant, tailored science briefings — personalized and easy to understand. Try 30 days free.
Follow:
No Comments
Share
SHARE

Key Highlights

•
Researchers have identified a key protein, TIE2, as the critical link between two major cellular signaling pathways that drive the growth of cerebral cavernous malformations (CCMs), which are abnormal blood vessel clusters in the brain. This discovery suggests that drugs targeting the TIE2 receptor could be a promising new strategy to treat these lesions and prevent associated strokes and seizures.
Source →

•
The study found that blocking TIE2 signaling, either genetically or with drugs, almost completely stopped the formation of CCMs in mouse models, while blocking a different receptor (VEGFR2) had no effect. This pinpointing of TIE2 as the specific driver offers a more precise and potentially effective therapeutic target for a condition that currently lacks good drug treatments.
Source →


Stay curious. Stay informed — with
Science Briefing.

Always double check the original article for accuracy.


Feedback

Share This Article
Facebook Flipboard Pinterest Whatsapp Whatsapp LinkedIn Tumblr Reddit Telegram Threads Bluesky Email Copy Link Print
Share
ByScience Briefing
Science Communicator
Follow:
Instant, tailored science briefings — personalized and easy to understand. Try 30 days free.
Previous Article Today’s Clinical Medicine Science Briefing | April 5th 2026, 9:00:31 am
Next Article Today’s Renewable Energy Science Briefing | April 5th 2026, 9:00:31 am
Leave a Comment Leave a Comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related Stories

Uncover the stories that related to the post!

How cells pay for the journey

A new metric to cut through the noise in evolutionary trees

A Sharper Lens on Species Detection: A New Model for Ecological Surveys

The birth of genes from scratch

A Cold Truth: Bergmann’s Rule Holds for Warm-Blooded Animals but Not for the Cold-Blooded

The Dimer’s Dilemma: Protein Structure and Drug Binding Dynamics

How Low Glucose Impairs mRNA Vaccine Delivery

A genetic recorder for the pancreas’s hidden workforce

Show More

Science Briefing delivers personalized, reliable summaries of new scientific papers—tailored to your field and interests—so you can stay informed without doing the heavy reading.

Science Briefing
  • Categories:
  • Medicine
  • Biology
  • Gastroenterology
  • Social Sciences
  • Surgery
  • Natural Language Processing
  • Chemistry
  • Cell Biology
  • Engineering
  • Neurology

Quick Links

  • My Feed
  • My Interests
  • History
  • My Saves

About US

  • Adverts
  • Our Jobs
  • Term of Use

ScienceBriefing.com, All rights reserved.

Personalize you Briefings
To Receive Instant, personalized science updates—only on the discoveries that matter to you.
Please enable JavaScript in your browser to complete this form.
Loading
Zero Spam, Cancel, Upgrade or downgrade anytime!
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?